

ESMO 2016 Industry Satellite Symposium

Immuno-Oncology in GU Cancer: Where Are We Today? Where Do We Go From Here?

Saturday, 8 October 2016 | 13:00–14:30

Helsinki Auditorium

Bella Center

Copenhagen, Denmark

Chair's invitation

Dear Colleagues,

Welcome to the ESMO 2016 Congress in Denmark.

We are excited to host this symposium on emerging research in immuno-oncology and are grateful for your participation. A recent approach to cancer therapeutics focuses on targeting the immune system to treat a variety of tumors. Immune evasion plays a key role in cancer pathogenesis and is an important target for drugs designed to harness the body's immune system against cancer.

In this symposium, we will discuss the current treatment paradigm in genitourinary cancers and highlight recent data and advancements in research efforts to develop potential new treatment options for genitourinary cancer.

Presentations include:

- Immuno-Oncology: Important Practical Information
- Latest Data in RCC: Enhancements in Survival and Tolerability
- Emerging Data on Immunotherapy in Metastatic Urothelial Carcinoma

These presentations aim to increase awareness regarding the important clinical differences between immuno-oncology and standard-of-care therapies for renal cell cancer and bladder cancer. Furthermore, they will highlight the advancements in research on immuno-oncology therapeutic options in these tumor types.

Bristol-Myers Squibb and the symposium faculty are committed to further develop the science and understanding of immuno-oncology therapeutic options in these tumor types and look forward to providing you with key information during this symposium.

Juergen Gschwend, MD, PhD
Symposium Chair
Technical University of Munich,
School of Medicine, Germany

Program

13:00 Welcome and Introductions

Juergen Gschwend, MD, PhD
Technical University of Munich
School of Medicine
Germany

13:05 Immuno-Oncology: Important Practical Information

Ignacio Duran, MD, PhD
University Hospital Virgen del Rocío
Spain

13:15 Latest Data in RCC: Enhancements in Survival and Tolerability

Manuela Schmidinger, MD
Medical University of Vienna
Austria

13:40 Emerging Data on Immunotherapy in Metastatic Urothelial Carcinoma

Sergio Bracarda, MD
Hospital of San Donato
Italy

14:05 Discussion and Q&A

Full Panel

14:25 Meeting Close